CHMP recommends letermovir as CMV prophylaxis

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for letermovir (Prevymis), which belongs to a class of non-nucleoside CMV inhibitors known as 3,4 dihydro-quinazolines. The CHMP is advocating that letermovir be approved as prophylaxis for cytomegalovirus (CMV) reactivation and... [Read Article]
Print Friendly, PDF & Email

Protein may be target for enhancing HSC transplants

Print Friendly, PDF & Email


Hematopoietic stem cells
in the bone marrow
Targeting the protein Del-1 could potentially improve hematopoietic stem cell (HSC) transplants, according to researchers. The team found that Del-1 promoted engraftment in murine transplant recipients, but the protein also promoted the retention of hematopoietic progenitors in the bone marrow of mice that received granulocyte colony-stimulating... [Read Article]
Print Friendly, PDF & Email

Team identifies HSCs that rapidly reconstitute hematopoiesis

Print Friendly, PDF & Email


Pig-tailed macaque
Researchers say they have identified a subpopulation of hematopoietic stem cells (HSCs) that immediately contributes to long-term, multilineage hematopoietic reconstitution after transplant. These HSCs were discovered in macaques, but the cells are similar to a subset of HSCs found in humans. The researchers found the 2 sets of cells behaved identically... [Read Article]
Print Friendly, PDF & Email

Ibrutinib approved to treat cGVHD in Canada

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
Health Canada has approved the BTK inhibitor ibrutinib (IMBRUVICA®) for the treatment of patients with steroid-dependent or -refractory chronic graft-versus-host disease (cGVHD). This is the sixth approval for ibrutinib in Canada. The drug is approved as monotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL), CLL... [Read Article]
Print Friendly, PDF & Email

Therapy receives rare pediatric disease designation

Print Friendly, PDF & Email


Micrograph showing
CMV infection
The US Food and Drug Administration (FDA) has granted rare pediatric disease designation to ATA230 for the treatment of congenital cytomegalovirus (CMV) infection. ATA230 is an allogeneic T-cell immunotherapy targeting antigens expressed by CMV. Rare pediatric disease designation is granted to drugs that show promise to treat orphan diseases affecting... [Read Article]
Print Friendly, PDF & Email

ATLG fights GVHD but reduces PFS, OS

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival in patients who have received a hematopoietic stem cell transplant (HSCT) from a matched, unrelated donor. In this randomized trial, ATLG significantly decreased the incidence... [Read Article]
Print Friendly, PDF & Email

Antibody can treat HSCT-TMA and GVHD, case suggests

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
A monoclonal antibody can resolve co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and graft-versus-host disease (GVHD), according to a case study. The antibody is OMS721, and it targets MASP-2, a pro-inflammatory protein target involved in activation of the complement system. The case of OMS721 ameliorating HSCT-TMA... [Read Article]
Print Friendly, PDF & Email